However, the identification of novel, and existing therapeutic strategies, that target both MCL1 and BCLXL to activate the intrinsic apoptosis pathway represent an attractive approach, although the delivery of cancer specific kill remains the greatest challenge to clinical translation of these strategies. The gene discussed is MCL1; the disease is cancer.